<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Several biotechnology and healthcare companies posted notable gains in after-hours trading on Wednesday, driven by clinical updates, financial results, and upcoming industry presentations.</p><p>ALX Oncology Holdings Inc. (ALXO) surged 10.17% to $1.30 after announcing positive data from a Phase 2 investigator-sponsored trial of its lead candidate, evorpacept. The therapy, combined with rituximab and lenalidomide, showed promise in patients with indolent B-cell non-Hodgkin lymphoma. The findings are scheduled to be presented on Sunday, December 7, at the American Society of Hematology (ASH) Annual Meeting 2025 in Orlando, Florida.</p><p>Globus Medical, Inc. (GMED) climbed 9.34% to $99.00 following the release of preliminary unaudited sales results. The company reported fourth-quarter 2025 sales of about $823.2 million, up 25.2% year-over-year. Full-year 2025 sales are expected to reach $2.936 billion, representing a 16.5% increase from the prior year. Looking ahead, Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share in the range of $4.30 to $4.40.</p><p>Acrivon Therapeutics, Inc. (ACRV) rose 6.44% to $3.14 after announcing plans to release clinical data updates for ACR-368 and ACR-2316. The company said it will issue a press release at 7:30 a.m. ET on January 8, 2026, followed by a conference call and webcast at 8:30 a.m. ET.</p><p>RenovoRx, Inc. (RNXT) gained 4.95% to $1.06 despite no company-specific news being reported on Wednesday.</p><p>AnaptysBio, Inc. (ANAB) advanced 1.75% to $46.00 after confirming that CEO Daniel Faga will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.</p><p>Omeros Corp. (OMER) added 4.47% to $14.72, also without any fresh corporate updates.</p><p>EUDA Health Holdings Limited (EUDA) increased 3.73% to $2.50 after announcing an amendment to its warrant agreement with Streeterville Capital, LLC. The Singapore-based healthcare provider operates across Singapore, Malaysia, and China, focusing on non-invasive medical services.</p><p>TherapeuticsMD, Inc. (TXMD) rose 5.34% to $2.15 in after-hours trading, with no new announcements reported.</p><p>Pyxis Oncology, Inc. (PYXS) gained 4.93% to $1.49, also without any fresh news on Wednesday. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

GMED

ALXO

ACRV

<p>Several biotechnology and healthcare companies saw significant after-hours gains on Wednesday due to clinical updates and financial results. ALX Oncology Holdings (ALXO) surged 10.17% after positive Phase 2 trial data. Globus Medical (GMED) climbed 9.34% on strong preliminary sales results, while Acrivon Therapeutics (ACRV) rose 6.44% ahead of upcoming clinical data releases. Other notable gainers included RenovoRx (RNXT), AnaptysBio (ANAB), Omeros Corp (OMER), EUDA Health (EUDA), TherapeuticsMD (TXMD), and Pyxis Oncology (PYXS).</p>

After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates